IDRA Annual EBIT
$98.10 M
+$210.76 M+187.08%
31 December 2021
Summary:
As of February 5, 2025, IDRA annual earnings before interest & taxes is $98.10 million, with the most recent change of +$210.76 million (+187.08%) on December 31, 2021. During the last 3 years, it has risen by +$157.97 million (+263.85%).IDRA EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
IDRA Quarterly EBIT
-$9.14 M
-$3.83 M-72.19%
30 September 2022
Summary:
As of February 5, 2025, IDRA quarterly earnings before interest & taxes is -$9.14 million, with the most recent change of -$3.83 million (-72.19%) on September 30, 2022. Over the past year, it has dropped by -$3.17 million (-53.19%).IDRA Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
IDRA TTM EBIT
-$22.74 M
-$3.17 M-16.21%
30 September 2022
Summary:
As of February 5, 2025, IDRA TTM earnings before interest & taxes is -$22.74 million, with the most recent change of -$3.17 million (-16.21%) on September 30, 2022. Over the past year, it has dropped by -$48.26 million (-189.12%).IDRA TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
IDRA EBIT Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +187.1% | -53.2% | -189.1% |
| 3 y3 years | +263.9% | +19.7% | +59.8% |
| 5 y5 years | +248.8% | +37.1% | +59.8% |
IDRA EBIT High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | ||||||
| 5 y | 5-year | ||||||
| alltime | all time | -0.0% | -107.9% | -123.2% |
Idera Pharmaceuticals EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2022 | - | -$9.14 M(+72.2%) | -$22.74 M(+16.2%) |
| June 2022 | - | -$5.31 M(+27.0%) | -$19.57 M(-10.3%) |
| Mar 2022 | - | -$4.18 M(+1.4%) | -$21.82 M(-122.2%) |
| Dec 2021 | $98.10 M(-187.1%) | -$4.12 M(-30.9%) | $98.10 M(+284.4%) |
| Sept 2021 | - | -$5.96 M(-21.1%) | $25.52 M(+133.4%) |
| June 2021 | - | -$7.56 M(-106.5%) | $10.93 M(-290.6%) |
| Mar 2021 | - | $115.74 M(-250.9%) | -$5.74 M(-94.9%) |
| Dec 2020 | -$112.66 M(+99.3%) | -$76.70 M(+273.2%) | -$112.66 M(+93.0%) |
| Sept 2020 | - | -$20.55 M(-15.2%) | -$58.38 M(+18.6%) |
| June 2020 | - | -$24.23 M(-374.8%) | -$49.21 M(+35.0%) |
| Mar 2020 | - | $8.82 M(-139.3%) | -$36.45 M(-35.5%) |
| Dec 2019 | -$56.52 M(-5.6%) | -$22.42 M(+97.0%) | -$56.52 M(+22.2%) |
| Sept 2019 | - | -$11.38 M(-0.8%) | -$46.25 M(-0.5%) |
| June 2019 | - | -$11.47 M(+2.0%) | -$46.47 M(-8.9%) |
| Mar 2019 | - | -$11.24 M(-7.4%) | -$51.03 M(-14.8%) |
| Dec 2018 | -$59.87 M(-9.2%) | -$12.15 M(+4.7%) | -$59.87 M(-4.4%) |
| Sept 2018 | - | -$11.61 M(-27.6%) | -$62.64 M(-4.4%) |
| June 2018 | - | -$16.03 M(-20.2%) | -$65.55 M(-7.7%) |
| Mar 2018 | - | -$20.09 M(+34.7%) | -$70.98 M(+7.7%) |
| Dec 2017 | -$65.93 M(+72.1%) | -$14.92 M(+2.7%) | -$65.93 M(+31.4%) |
| Sept 2017 | - | -$14.52 M(-32.3%) | -$50.18 M(+3.4%) |
| June 2017 | - | -$21.46 M(+42.7%) | -$48.54 M(+19.7%) |
| Mar 2017 | - | -$15.04 M(-1892.7%) | -$40.55 M(+5.8%) |
| Dec 2016 | -$38.31 M(-20.9%) | $839.00 K(-106.5%) | -$38.31 M(-25.1%) |
| Sept 2016 | - | -$12.88 M(-4.3%) | -$51.11 M(+3.1%) |
| June 2016 | - | -$13.46 M(+5.2%) | -$49.57 M(+1.6%) |
| Mar 2016 | - | -$12.80 M(+7.0%) | -$48.80 M(+0.7%) |
| Dec 2015 | -$48.45 M(+25.5%) | -$11.97 M(+5.5%) | -$48.45 M(+0.2%) |
| Sept 2015 | - | -$11.34 M(-10.7%) | -$48.38 M(+4.1%) |
| June 2015 | - | -$12.69 M(+1.9%) | -$46.49 M(+10.4%) |
| Mar 2015 | - | -$12.45 M(+4.7%) | -$42.13 M(+9.0%) |
| Dec 2014 | -$38.62 M(+112.5%) | -$11.89 M(+25.8%) | -$38.65 M(+17.7%) |
| Sept 2014 | - | -$9.46 M(+13.5%) | -$32.83 M(+17.0%) |
| June 2014 | - | -$8.33 M(-7.2%) | -$28.06 M(+20.4%) |
| Mar 2014 | - | -$8.97 M(+47.8%) | -$23.29 M(+28.2%) |
| Dec 2013 | -$18.17 M(-8.7%) | -$6.07 M(+29.7%) | -$18.17 M(+10.6%) |
| Sept 2013 | - | -$4.68 M(+31.3%) | -$16.43 M(-0.4%) |
| June 2013 | - | -$3.57 M(-7.3%) | -$16.50 M(-9.6%) |
| Mar 2013 | - | -$3.85 M(-11.2%) | -$18.26 M(-8.3%) |
| Dec 2012 | -$19.90 M(-23.0%) | -$4.33 M(-8.8%) | -$19.90 M(-12.7%) |
| Sept 2012 | - | -$4.75 M(-10.7%) | -$22.80 M(-3.3%) |
| June 2012 | - | -$5.32 M(-3.1%) | -$23.57 M(-3.9%) |
| Mar 2012 | - | -$5.49 M(-24.0%) | -$24.52 M(-5.2%) |
| Dec 2011 | -$25.86 M(+44.0%) | -$7.23 M(+31.0%) | -$25.86 M(+5.1%) |
| Sept 2011 | - | -$5.52 M(-12.1%) | -$24.59 M(+2.6%) |
| June 2011 | - | -$6.28 M(-8.1%) | -$23.97 M(+4.0%) |
| Mar 2011 | - | -$6.83 M(+14.4%) | -$23.05 M(+28.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2010 | -$17.96 M(-339.3%) | -$5.97 M(+22.1%) | -$17.96 M(+120.3%) |
| Sept 2010 | - | -$4.89 M(-8.8%) | -$8.15 M(+152.9%) |
| June 2010 | - | -$5.36 M(+207.8%) | -$3.22 M(-153.0%) |
| Mar 2010 | - | -$1.74 M(-145.4%) | $6.09 M(-18.9%) |
| Dec 2009 | $7.50 M(+375.9%) | $3.84 M(+9490.0%) | $7.50 M(+52.3%) |
| Sept 2009 | - | $40.00 K(-99.0%) | $4.93 M(-24.2%) |
| June 2009 | - | $3.95 M(-1323.2%) | $6.50 M(+89.5%) |
| Mar 2009 | - | -$323.00 K(-125.6%) | $3.43 M(+117.6%) |
| Dec 2008 | $1.58 M(-110.7%) | $1.26 M(-21.9%) | $1.58 M(-135.0%) |
| Sept 2008 | - | $1.61 M(+83.2%) | -$4.50 M(-53.4%) |
| June 2008 | - | $881.00 K(-140.4%) | -$9.66 M(-30.8%) |
| Mar 2008 | - | -$2.18 M(-54.8%) | -$13.96 M(-5.2%) |
| Dec 2007 | -$14.73 M(-11.1%) | -$4.82 M(+36.0%) | -$14.73 M(+0.4%) |
| Sept 2007 | - | -$3.54 M(+3.4%) | -$14.66 M(-1.9%) |
| June 2007 | - | -$3.42 M(+16.3%) | -$14.95 M(-5.9%) |
| Mar 2007 | - | -$2.94 M(-38.1%) | -$15.89 M(-4.1%) |
| Dec 2006 | -$16.56 M(+19.8%) | -$4.76 M(+24.1%) | -$16.56 M(+5.5%) |
| Sept 2006 | - | -$3.83 M(-12.0%) | -$15.69 M(+6.0%) |
| June 2006 | - | -$4.36 M(+20.4%) | -$14.81 M(+4.6%) |
| Mar 2006 | - | -$3.62 M(-6.9%) | -$14.15 M(+2.4%) |
| Dec 2005 | -$13.82 M(+7.0%) | -$3.89 M(+31.8%) | -$13.82 M(+7.7%) |
| Sept 2005 | - | -$2.95 M(-20.3%) | -$12.83 M(-8.0%) |
| June 2005 | - | -$3.70 M(+12.4%) | -$13.95 M(+3.5%) |
| Mar 2005 | - | -$3.29 M(+13.5%) | -$13.47 M(+4.3%) |
| Dec 2004 | -$12.92 M(-25.7%) | -$2.90 M(-28.7%) | -$12.92 M(-11.1%) |
| Sept 2004 | - | -$4.06 M(+26.2%) | -$14.53 M(+2.9%) |
| June 2004 | - | -$3.22 M(+17.6%) | -$14.12 M(-6.2%) |
| Mar 2004 | - | -$2.74 M(-39.2%) | -$15.05 M(-14.5%) |
| Dec 2003 | -$17.39 M(-208.9%) | -$4.51 M(+23.3%) | -$17.61 M(+3.8%) |
| Sept 2003 | - | -$3.65 M(-11.9%) | -$16.97 M(-282.2%) |
| June 2003 | - | -$4.15 M(-21.7%) | $9.31 M(-21.8%) |
| Mar 2003 | - | -$5.30 M(+37.2%) | $11.91 M(-25.4%) |
| Dec 2002 | $15.97 M(+51.3%) | -$3.86 M(-117.1%) | $15.97 M(-58.3%) |
| Sept 2002 | - | $22.63 M(-1558.0%) | $38.30 M(+177.6%) |
| June 2002 | - | -$1.55 M(+25.4%) | $13.80 M(+15.9%) |
| Mar 2002 | - | -$1.24 M(-106.7%) | $11.90 M(+11.3%) |
| Dec 2001 | $10.56 M(-261.4%) | $18.47 M(-1082.5%) | $10.69 M(-216.4%) |
| Sept 2001 | - | -$1.88 M(-45.5%) | -$9.18 M(+6.5%) |
| June 2001 | - | -$3.45 M(+40.9%) | -$8.63 M(+25.5%) |
| Mar 2001 | - | -$2.45 M(+73.8%) | -$6.87 M(+5.7%) |
| Dec 2000 | -$6.54 M(-22.9%) | -$1.41 M(+6.5%) | -$6.50 M(+27.7%) |
| Sept 2000 | - | -$1.32 M(-21.9%) | -$5.09 M(+35.1%) |
| June 2000 | - | -$1.69 M(-18.4%) | -$3.77 M(+81.6%) |
| Mar 2000 | - | -$2.08 M | -$2.08 M |
| Dec 1999 | -$8.48 M(-63.2%) | - | - |
| Dec 1998 | -$23.05 M(-57.2%) | - | - |
| Dec 1997 | -$53.91 M(+15.4%) | - | - |
| Dec 1996 | -$46.73 M | - | - |
FAQ
- What is Idera Pharmaceuticals annual earnings before interest & taxes?
- What is the all time high annual EBIT for Idera Pharmaceuticals?
- What is Idera Pharmaceuticals annual EBIT year-on-year change?
- What is Idera Pharmaceuticals quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Idera Pharmaceuticals?
- What is Idera Pharmaceuticals quarterly EBIT year-on-year change?
- What is Idera Pharmaceuticals TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Idera Pharmaceuticals?
- What is Idera Pharmaceuticals TTM EBIT year-on-year change?
What is Idera Pharmaceuticals annual earnings before interest & taxes?
The current annual EBIT of IDRA is $98.10 M
What is the all time high annual EBIT for Idera Pharmaceuticals?
Idera Pharmaceuticals all-time high annual earnings before interest & taxes is $98.12 M
What is Idera Pharmaceuticals annual EBIT year-on-year change?
Over the past year, IDRA annual earnings before interest & taxes has changed by +$210.76 M (+187.08%)
What is Idera Pharmaceuticals quarterly earnings before interest & taxes?
The current quarterly EBIT of IDRA is -$9.14 M
What is the all time high quarterly EBIT for Idera Pharmaceuticals?
Idera Pharmaceuticals all-time high quarterly earnings before interest & taxes is $115.74 M
What is Idera Pharmaceuticals quarterly EBIT year-on-year change?
Over the past year, IDRA quarterly earnings before interest & taxes has changed by -$3.17 M (-53.19%)
What is Idera Pharmaceuticals TTM earnings before interest & taxes?
The current TTM EBIT of IDRA is -$22.74 M
What is the all time high TTM EBIT for Idera Pharmaceuticals?
Idera Pharmaceuticals all-time high TTM earnings before interest & taxes is $98.10 M
What is Idera Pharmaceuticals TTM EBIT year-on-year change?
Over the past year, IDRA TTM earnings before interest & taxes has changed by -$48.26 M (-189.12%)